The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Abstract
BACKGROUND: High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival. METHODS: Between October 1998 and February 2004, 668 patients with newly diagnosed multiple myeloma received two cycles of intensive melphalan-based chemotherapy, each supported by autologous hematopoietic stem-cell transplantation. A total of 323 were randomly assigned to receive thalidomide from the outset until disease progression or undue adverse effects, and 345 did not receive thalidomide. The primary end point was the five-year event-free survival rate. Secondary end points were complete response and overall survival. RESULTS: After a median follow-up of 42 months among survivors, the thalidomide and control groups had rates of complete response of 62 percent and 43 percent, respectively (P<0.001), and five-year event-free survival rates of 56 percent and 44 percent (P=0.01). The five-year rate of overall survival was approximately 65 percent in both groups (P=0.90). Median survival after relapse was 1.1 years in the thalidomide group and 2.7 years in the control group (P=0.001). Severe peripheral neuropathy and deep-vein thrombosis occurred more frequently in the thalidomide group than in the control group. CONCLUSIONS: When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival. (ClinicalTrials.gov number, NCT00083551.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationGooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Self-citationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Self-citationMAQC Consortium (2010) · Nature Biotechnology · doi:10.1038/nbt.1665 · Cited by 889
“Gene expression profiling of highly purified bone marrow plasma cells was performed in newly diagnosed patients with M”
BackgroundMultiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., San Miguel, J., Sonneveld, P., Mateos, M. V., Zamagni, E., Avet-Loiseau, H., Hajek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 877
Facon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 869
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citationChemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R., Pettitt, A., Hamblin, T., Milligan, D., Child, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61125-8 · Cited by 677
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I. Y., Bourhis, J.-H., Garderet, L., Pegourie, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 667
Chen, M., Zhao, Y., Xu, C., Wang, X., Zhang, X., & Mao, B. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3284-y · Cited by 647
Loehrer, P. J. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79037-7 · Cited by 602
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 559
Self-citationRecent major improvement in long-term survival of younger patients with multiple myeloma
Brenner, H., Gondos, A., & Pulte, D. (2008) · Blood · doi:10.1182/blood-2007-08-104984 · Cited by 535
Hanamura, I., Stewart, J. P., Huang, Y., Zhan, F., Santra, M., Sawyer, J. R., Hollmig, K., Zangarri, M., Pineda-Roman, M., van Rhee, F., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009910 · Cited by 479
Self-citationTai, Y.-T., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2008) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 473
Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 433
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Carrasco, D. R., Tonon, G., Huang, Y., Zhang, Y., Sinha, R., Feng, B., Stewart, J. P., Zhan, F., Khatry, D., Protopopova, M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.019 · Cited by 425
Self-citationSpatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00296-y · Cited by 417
Self-citationMagnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
Walker, R., Barlogie, B., Haessler, J., Tricot, G., Anaissie, E., Shaughnessy, J. D., Epstein, J., van Hemert, R., Erdem, E., Hoering, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5803 · Cited by 417
Self-citationZhan, F., Barlogie, B., Arzoumanian, V., Huang, Y., Williams, D. R., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Zangari, M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-037077 · Cited by 381
Self-citationCavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2509 · Cited by 370
Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358812 · Cited by 352
Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Hockaday, A., Jones, J. R., Kishore, B., Garg, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30687-9 · Cited by 348
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
Self-citationSpencer, A., Prince, H. M., Roberts, A. W., Prosser, I. W., Bradstock, K. F., Coyle, L., Gill, D. S., Horvath, N., Reynolds, J., & Kennedy, N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8573 · Cited by 332
Barlogie, B., Anaissie, E., Van Rhee, F., Haessler, J., Hollmig, K., Pineda‐Roman, M., Cottler‐Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06639.x · Cited by 331
Self-citationMorgan, G. J., Gregory, W. M., Davies, F. E., Bell, S. E., Szubert, A. J., Brown, J. M., Coy, N. N., Cook, G., Russell, N. H., Rudin, C., et al. (2012) · Blood · doi:10.1182/blood-2011-06-357038 · Cited by 331
Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omedè, P., Ambrosini, M. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3463 · Cited by 319
Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., Sezer, O., Ludwig, H., Dimopoulos, M. A., Attal, M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-297325 · Cited by 314
Thalidomide for treatment of multiple myeloma: 10 years later
Palumbo, A., Facon, T., Sonneveld, P., Bladè, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117457 · Cited by 313
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Burgess, J., Ferdousi, M., Gosal, D., Boon, C., Matsumoto, K., Marshall, A., Mak, T., Marshall, A., Frank, B., Malik, R. A., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00168-y · Cited by 306
Guidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 306
Azoulay, É., Mokart, D., Lambert, J., Lemiale, V., Rabbat, A., Kouatchet, A., Vincent, F., Gruson, D., Bruneel, F., Epinette-Branche, G., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0018oc · Cited by 300
Zhou, W., Yang, Y., Xia, J., Wang, H., Salama, M. E., Xiong, W., Xu, H., Shetty, S., Chen, T., Zeng, Z., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.001 · Cited by 288
Self-citationvan de Velde, H. J. K., Liu, X., Chen, G., Cakana, A., Deraedt, W., & Bayssas, M. (2007) · Haematologica · doi:10.3324/haematol.11534 · Cited by 283
Lahuerta, J. J., Mateos, M. V., Martínez-López, J., Rosiñol, L., Sureda, A., de la Rubia, J., García-Laraña, J., Martínez-Martínez, R., Hernández-García, M. T., Carrera, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9721 · Cited by 279
Lokhorst, H. M., van der Holt, B., Zweegman, S., Vellenga, E., Croockewit, S., van Oers, M. H., von dem Borne, P., Wijermans, P., Schaafsma, R., de Weerdt, O., et al. (2010) · Blood · doi:10.1182/blood-2009-05-222539 · Cited by 276
Krishnan, A., Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70243-1 · Cited by 274
Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Crippa, C., De Rosa, L., Pregno, P., Grasso, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7172 · Cited by 267
Jagannath, S., Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Cowan, J. M., & Anderson, K. C. (2007) · Leukemia · doi:10.1038/sj.leu.2404442 · Cited by 264
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S. V., et al. (2012) · Leukemia · doi:10.1038/leu.2011.346 · Cited by 253
Association of response endpoints with survival outcomes in multiple myeloma
Lonial, S., & Anderson, K. C. (2014) · Leukemia · doi:10.1038/leu.2013.220 · Cited by 162
Prospective study of religious coping among patients undergoing autologous stem cell transplantation
Sherman, A. C., Plante, T. G., Simonton, S., Latif, U., & Anaissie, E. J. (2009) · Journal of Behavioral Medicine · doi:10.1007/s10865-008-9179-y · Cited by 141
Self-citationCancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
The Glycome of Normal and Malignant Plasma Cells
Moehler, T. M., Seckinger, A., Hose, D., Andrulis, M., Moreaux, J., Hielscher, T., Willhauck-Fleckenstein, M., Merling, A., Bertsch, U., Jauch, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083719 · Cited by 17
Metadata
- Authors
- Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M., & Crowley, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-09
- Volume
- 354
- Issue
- 10
- Pages
- 1021-1030
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2136373453
- Cited by
- 739
- References
- 34
- FWCI
- 53.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.